Ülke: İrlanda
Dil: İngilizce
Kaynak: HPRA (Health Products Regulatory Authority)
Lanreotide acetate
Ipsen Pharmaceuticals Limited
H01CB; H01CB03
Lanreotide acetate
60 milligram(s)
Solution for injection in pre-filled syringe
Product subject to prescription which may not be renewed (A)
Somatostatin and analogues; lanreotide
Marketed
2002-02-22
Page 1 of 11 PACKAGE LEAFLET: INFORMATION FOR THE USER SOMATULINE AUTOGEL 60 MG, SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE SOMATULINE AUTOGEL 90 MG, SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE SOMATULINE AUTOGEL 120 MG, SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE Lanreotide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Somatuline Autogel is and what it is used for 2. What you need to know before you use Somatuline Autogel 3. How to use Somatuline Autogel 4. Possible side effects 5. How to store Somatuline Autogel 6. Contents of the pack and other information 1. WHAT SOMATULINE AUTOGEL IS AND WHAT IT IS USED FOR WHAT SOMATULINE AUTOGEL IS AND HOW IT WORKS The name of your medicine is Somatuline Autogel. It is a long acting formulation of Somatuline. Lanreotide, the active substance, belongs to a group of medicines called ‘antigrowth hormones’. It is similar to another substance (a hormone) called ‘somatostatin’. Lanreotide lowers the levels of hormones in the body such as growth hormone (GH), and insulin-like growth factor 1 (IGF-1) and inhibits the release of some hormones in the gastrointestinal tract and intestinal secretions. Additionally, it has an effect on some advanced type of tumours (called neuroendocrine tumours) of the intestine and pancreas by stopping or delaying their growth. WHAT SOMATULINE AUTOGEL IS USED FOR: • The long term treatment of acromegaly (a condition where your body produces too much growth hormone) • The relief of symptoms associated wi Belgenin tamamını okuyun
Health Products Regulatory Authority 21 August 2023 CRN00DF4D Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Somatuline Autogel 60 mg, solution for injection in a prefilled syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains a supersaturated solution of lanreotide acetate corresponding to 0.246 mg of lanreotide base/mg of solution, which ensures an actual injection dose of 60 mg of lanreotide. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection in a pre-filled syringe. White to pale yellow semi solid formulation. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Somatuline Autogel is indicated for: The long-term treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalise these values. The relief of symptoms associated with acromegaly. The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease (see section 5.1). The treatment of symptoms associated with carcinoid tumours. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology ACROMEGALY The recommended starting dose is 60 to 120 mg administered every 28 days. For example, in patients previously treated with Somatuline LA 30 mg with a dose every 14 days, the initial dose of Somatuline Autogel should be 60 mg every 28 days, and in patients previously treated with Somatuline LA 30 mg with a dose every 10 days, the initial dose of Somatuline Autogel should be 90 mg every 28 days. Thereafter the dose should be individualised according to the r Belgenin tamamını okuyun